Completed OBSERVATIONAL NCT04714515

Montelukast - a Treatment Choice for COVID-19

Using Montelukast to Treat the Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Interventions Hydroxychloroquine Ivermectin Montelukast

Updated 4 times since 2021 Last updated: Jan 15, 2021 Started: Feb 20, 2020 Primary completion: Mar 30, 2020 Completion: Apr 20, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Covid19 and SARS-CoV-2 Infection and is currently completed. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine leads this study, which shows 4 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Feb 2021 — Dec 2021 [monthly]

Completed

First recorded

Feb 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Jiao Tong University School of Medicine
Shaukat Khanum Memorial Cancer Hospital & Research Centre
Teesside University
University of Sargodha

Data source: University of Sargodha

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lahore, Pakistan
• Shanghai, China